<DOC>
	<DOCNO>NCT01240876</DOCNO>
	<brief_summary>The primary objective study evaluate safety efficacy CEP-37247 compare placebo assess occurrence adverse event , mean change average pain intensity ( API ) affect leg .</brief_summary>
	<brief_title>Study Evaluate Safety Efficacy Placulumab ( CEP-37247 ) Administered Transforaminal Epidural Route Treatment Patients With Lumbosacral Radicular Pain Associated With Disk Herniation</brief_title>
	<detailed_description />
	<mesh_term>Sciatica</mesh_term>
	<criteria>Over 4 day prior randomization visit , patient mean score great equal 5 ( 10 ) `` Average Pain Over Past 24 Hours '' pain affect leg assess 11Point Numerical Rating Scale ( NRS11 ) capture electronic diary . The patient must valid ( nonmissing ) data least 3 4 day , mean score must least 5 without round . The patient current diagnosis lumbosacral radicular pain . Pain must radiate leg dermatomal/myotomal distribution consistent diagnosis lumbosacral radicular pain suspect involved nerve root . Based history medical record ( available ) , duration current episode pain must 6 52 week duration . Diagnosis must confirm magnetic resonance imaging ( MRI ) ( exist compute tomography [ CT ] MRI relate symptom present screen ) perform within 6 month prior screen demonstrate disk herniation location consistent clinical symptom radicular pain . Other incidental pathology permit long asymptomatic believe causal primary diagnosis lumbosacral radicular pain specific spinal level describe . The patient must least 1 follow : positive straight leg raise ( L5S1 ) , positive femoral stretch test ( L3L4 ) , positive test result upon physical examination consistent presence nerve root irritation nerve root suspect involve diagnosed lumbosacral radicular pain screening . Herniation must affect L3L4 , L4L5 , L5S1 must consistent clinical presentation current episode lumbosacral radicular pain describe . Patients significant progressive sensory impairment motor impairment ( foot drop ) must assess casebycase basis investigator , must case receive write approval Sponsor prior randomization . There must confirmation patient active tuberculosis infection screening . The patient either negative QuantiFERON®TB Gold blood test negative tuberculin skin test ( TST ) result screening ; however QuantiFERON®TB Gold test TST positive , chest radiogram may use determine whether patient active infection . The patient willing keep analgesic medication therapy usage ( physiotherapy , acupuncture , transcutaneous electrical nerve stimulation [ TENS ] ) stable decrease study use rescue pain medication need specify protocol . The patient good health ( exception condition study ) determine medical psychiatric history , medical examination , ECG , serum chemistry , hematology , urinalysis , serology . Women childbearing potential ( ie , surgically sterile 2 year postmenopausal ) , must use medically accept method contraception must agree continue use method duration study 30 day participation study , negative pregnancy test screening . The patient : documented history allergic reaction ( hive , rash , etc . ) clinically significant intolerance study drug ingredient . body mass index ( BMI ) great 40 kg/m2 . patient establish history major psychiatric disorder , control medication appear anxiety would interfere clinical pain score participation trial . clinically significant abnormality clinical chemistry , hematology urinalysis , include serum glutamicoxaloacetic transaminase/aspartate aminotransferase ( AST ) serum glutamicpyruvic transaminase/alanine aminotransferase ( ALT ) great equal 3 time upper limit reference range estimate glomerular filtration rate ( eGFR ) less equal 30 mL/min/1.73 m2 ( Modification Diet Renal Disease [ MDRD ] study formula ) screening . receive intraepidural steroid injection treatment current episode sciatica last 3 month prior screen . significant pain unrelated disk herniation would significantly compromise assessment radicular back leg pain related disk herniation . radiologic evidence disk herniation 1 spinal level , clinical evidence lumbosacral radicular pain 1 spinal nerve corresponding level multiple disk herniation . receive investigational drug within 30 day prior screen , schedule receive investigational drug blind study drug course study . lumbar sacral back surgery relate specific disk cause radicular pain upon presentation study , currently plan undergo spine surgical intervention study . receive epidural corticosteroid injection back within 3 month screen . involve ongoing worker 's compensation claim , disability claim , litigation relate pain problem . active infection selflimiting resolve prior study drug administration . history malignancy evidence malignancy lymphoproliferative neoplastic disease exception successfully treat basal squamous cell carcinoma skin cervical intraepithelial neoplasia within 5 year screen visit . history systemic fungal infection . history opportunistic infection within 3 month prior screen . history know suspected chronic infection , tuberculosis , hepatitis B virus ( HBV ) , hepatitis C virus ( HCV ) , Human Immunodeficiency Virus ( HIV ) . The investigator review medical history ( include medication history ) , patient find HIV positive base medical review exclude study . history demyelinate disease , include multiple sclerosis optic neuritis . use antitumor necrosis factor ( TNF ) receptor medication ( anakinra [ KINERET® , Biovitrum ] ) antiTNF medication ( etanercept [ ENBREL® , Amgen Inc. ] , infliximab [ REMICADE® , Centocor Ortho Biotech Inc. ] , adalimumab [ HUMIRA® , Abbott Laboratories ] , experimental TNF inhibitor ) within past year . plan joint replacement surgery history infect joint prosthesis receive antibiotic suspected infection joint prosthesis prosthesis remove replace . give live vaccine within 14 day study drug administration . severe spinal stenosis spondylolisthesis ( grade 2 high ) . coagulopathy . pregnant lactate woman ( woman become pregnant study withdrawn study ) . history diabetic neuropathy peripheral neuropathy low extremity . history condition ( otherwise specify ) know amenable TNF inhibitor ( e.g. , Crohn 's disease ) . know allergy idiosyncratic ( atopic ) reaction contrast agent , local anesthetic , study drug , ingredient list present study formulation , pain management compound likely prescribed study , include metabolite ( applicable ) ingredient list present formulation . clinically significant uncontrolled medical condition ( treat untreated ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Sciatica</keyword>
	<keyword>Pain</keyword>
</DOC>